Skip to content

Tilray Brands, Inc. TLRY Equity Method Investments

Equity Method Investments at other companies

Canopy Growth Corporation logo
Canopy Growth CorporationCGC
$49.83M
Opko Health logo
Opko HealthOPK
$10.53M-17.4%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$34.35M+64.3%
TG Therapeutics logo
TG TherapeuticsTGTX
$61.54M+3,127%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$61.53M-52.0%

Other financials

Income statement

See full
Revenue$206.7M+11.3%
Gross profit$55.0M+5.7%
Operating income-$26.4M+96.5%
Net income-$26.6M+96.6%
EPS (diluted)-$0.24+97.2%

Balance sheet

See full
Cash & equivalents$204.6M+2.3%
Total debt$211.4M-6.9%
Total equity$1.6B-42.9%
Total assets$2.1B-39.0%

Cash flow

See full
Operating cash flow-$21.9M-281%
CapEx$6.3M-34.8%
Free cash flow-$19.1M

Valuation

See full
Market cap$538.85M+47.3%
Enterprise value$545.59M+46.8%
P/S0.6×+0.2×

Profitability

See full
Gross margin30.9%+2.9pp
Operating margin-103.5%-198pp
Net margin-156.1%+89.5pp
FCF margin-15.5%

Returns & leverage

See full
Return on equity-62.5%-1,636pp
Debt / equity0.1×+0.1×
Current ratio2.8×+0.2×

Where this comes from

Reported directly by Tilray Brands, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermInvestments.

The official record: Tilray Brands, Inc.’s 10-Q, filed April 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tilray Brands, Inc.'s equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tilray Brands, Inc.'s equity method investments?
Tilray Brands, Inc. (TLRY) reported equity method investments of $7.63M in Q4 2025.
What is the long-term trend for Tilray Brands, Inc.'s equity method investments?
Over 4 years (2021 to 2025), Tilray Brands, Inc.'s equity method investments has grown at a -13.0% compound annual growth rate (CAGR), from $17.69M to $10.13M.
What does equity method investments mean?
Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.